771 related articles for article (PubMed ID: 31912605)
1. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
Damman K; Beusekamp JC; Boorsma EM; Swart HP; Smilde TDJ; Elvan A; van Eck JWM; Heerspink HJL; Voors AA
Eur J Heart Fail; 2020 Apr; 22(4):713-722. PubMed ID: 31912605
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
4. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
Schulze PC; Bogoviku J; Westphal J; Aftanski P; Haertel F; Grund S; von Haehling S; Schumacher U; Möbius-Winkler S; Busch M
Circulation; 2022 Jul; 146(4):289-298. PubMed ID: 35766022
[TBL] [Abstract][Full Text] [Related]
5. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
[TBL] [Abstract][Full Text] [Related]
6. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
7. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
8. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
de Boer RA; Núñez J; Kozlovski P; Wang Y; Proot P; Keefe D
Br J Clin Pharmacol; 2020 Jul; 86(7):1346-1356. PubMed ID: 32068914
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Cox ZL; Collins SP; Aaron M; Hernandez GA; Iii ATM; Davidson BT; Fowler M; Lindsell CJ; Jr FEH; Jenkins CA; Kampe C; Miller KF; Stubblefield WB; Lindenfeld J
Am Heart J; 2021 Feb; 232():116-124. PubMed ID: 33144086
[TBL] [Abstract][Full Text] [Related]
11. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
12. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
Boorsma EM; Beusekamp JC; Ter Maaten JM; Figarska SM; Danser AHJ; van Veldhuisen DJ; van der Meer P; Heerspink HJL; Damman K; Voors AA
Eur J Heart Fail; 2021 Jan; 23(1):68-78. PubMed ID: 33251643
[TBL] [Abstract][Full Text] [Related]
13. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Tripolt NJ; Kolesnik E; Pferschy PN; Verheyen N; Ablasser K; Sailer S; Alber H; Berger R; Kaulfersch C; Leitner K; Lichtenauer M; Mader A; Moertl D; Oulhaj A; Reiter C; Rieder T; Saely CH; Siller-Matula J; Weidinger F; Zechner PM; von Lewinski D; Sourij H;
Am Heart J; 2020 Mar; 221():39-47. PubMed ID: 31901799
[TBL] [Abstract][Full Text] [Related]
14. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
Tromp J; Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Blatchford JP; Steubl D; Voors AA
Eur J Heart Fail; 2024 Apr; 26(4):963-970. PubMed ID: 38572654
[TBL] [Abstract][Full Text] [Related]
15. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
16. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Abraham WT; Lindenfeld J; Ponikowski P; Agostoni P; Butler J; Desai AS; Filippatos G; Gniot J; Fu M; Gullestad L; Howlett JG; Nicholls SJ; Redon J; Schenkenberger I; Silva-Cardoso J; Störk S; Krzysztof Wranicz J; Savarese G; Brueckmann M; Jamal W; Nordaby M; Peil B; Ritter I; Ustyugova A; Zeller C; Salsali A; Anker SD
Eur Heart J; 2021 Feb; 42(6):700-710. PubMed ID: 33351892
[TBL] [Abstract][Full Text] [Related]
17. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
[TBL] [Abstract][Full Text] [Related]
18. The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF).
Emara AN; Wadie M; Mansour NO; Shams MEE
Eur J Pharmacol; 2023 Dec; 961():176179. PubMed ID: 37923161
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
[TBL] [Abstract][Full Text] [Related]
20. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
